Molecular genetics of microvascular disease in diabetic retinopathy

Eye

Volumn 17, Issue 3, 2003, Pages 305-311

  Warpeha, K M ^a   Chakravarthy, U ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Diabetic retinopathy; Genetic susceptibility; Polymorphisms

Indexed keywords

ALDEHYDE REDUCTASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; BETA 3 ADRENERGIC RECEPTOR; BETA1 INTEGRIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; GLUCOSE TRANSPORTER 1; GUANINE NUCLEOTIDE BINDING PROTEIN; HLA ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; NEUROPEPTIDE Y; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR; TUMOR NECROSIS FACTOR;

ACCURACY; CHROMOSOME 6P; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEALTH STATUS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MARKER GENE; MICROANGIOPATHY; MOLECULAR GENETICS; PATHOGENESIS; POPULATION RESEARCH; RETINA BLOOD VESSEL; REVIEW; SAMPLE SIZE;

EID: 0037617928     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700348     Document Type: Review

References (73)

1. Nebert DW, Petersen DD, Puga A. Human A locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991; 1: 68-78.
2. Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A diabetes. Recent Prog Horm Res 2001; 56: 69-89.
3. Moss SE, Klein R, Klein BEK. 10-year incidence of visual loss in a diabetic population. Ophthalmology 1994; 101: 1061-1070.
4. Diabetes Control and Complications Trial Research Group. Clustering of long term complications in families with diabetes in the Diabetes Control & Complication Trial. Diabetes 1997; 46: 1829-1839.
5. Leslie RDG, Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982; 31: 19-21.
6. Guillausseau PJ, Tielmans D, Virally-Monod M, Assayag M. Diabetes: from phenotypes to genotypes. Diabetes Metab 1997; 23: 14-21.
7. Cruickshanks KJ, Vadheim CM, Moss SE, Roth MP, Riley WJ, MacLaren NK. Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age. Diabetes 1992; 41: 879-885.
8. Rich SS, Freedman BI, Bowden DW. Genetic epidemiology of diabetic complications. Diabetic Rev 1997; 5: 165-173.
9. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 1998; 47: 821-830.
10. Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA. Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. Histochem J 1993; 25: 648-663.
11. Patel A, Hibberd ML, Millward BA, Demaine AG. Chromosome 7q35 and susceptibility to diabetic micro-vascular complications. J Diabetes Complications 1996; 10: 62-67.
12. Pfeiffer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: The end of an era or the need for different trial designs? Diabetes 1994; 42: S82-S89.
13. Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I Diabetes. Diabetes 1997; 46: 287-291.
14. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998; 64: 213-216.
15. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with Type 1 diabetes. Diabetes 1999; 48: 1338-1340.
16. Olmos P, Acosta AM, Schaffiano R, Diaz R, Alvarado D, O'Brien A et al. Aldose reductase gene polymorphism and rate of appearance of retinopathy in non-insulin dependent diabetics. Rev Med Chile 1999; 127: 399-409.
17. Ko BCB, Lam KSL, Wat NMS, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early onset diabetic retinopathy in NIDDM patients. Diabetes 1995; 44: 727-732.
18. Fujisawa T, Ikegami H, Kawaguchi Y, Yamato E, Nakagawa Y, Shen GQ et al. Length rather than a specific allele of dinucleotide repeat in the 5′ upstream region of the aldose reductase gene is associated with diabetic retinopathy. Diabetic Med 1999; 16: 1044-1047.
19. Ichikawa F, Yamada K, Ishiyama-Shigemoto S, Yuan X, Nonaka K. Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5′-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus. Diabetic Med 1999; 16: 744-748.
20. Ikegishi Y, Tawata M, Aida K, Onaya T. Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. Life Sci 1999; 65: 2061-2070.
21. Chistiakov DA, Turakulov RI, Gorashko NM, Demurov LM, Rachiba IuM, Kondrat Ia.Iu. Polymorphism of a dinucleotide repeat within the aldose reductase gene in normalcy and insulin-dependent diabetes with vascular complications. Mol Biol 1997; 31: 660-664.
22. Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41: 4064-4068.
23. Cisse A, Chauffert M Diop SN, Chevenne D, Sidibe EH, Michel S et al HLA markers and diabetic retinopathy in the Senegalese population. Dakar Med 1998; 43: 29-33.
24. Falck AA, Knip JM, Ilonen JS, Laatikainen LT. Genetic markers in early diabetic retinopathy of adolescents with type I diabetes. J Diabetes Complications 1997; 11: 203-207.
25. Agardh D, Gaur LK, Agardh E, Landin-Olsson M, Agardh CD, Lernmark A. HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM. Diabetologia 1996; 39: 1313-1317.
26. Stewart LL, Field LL, Ross S, McArthur RG. Genetic risk factors in diabetic retinopathy. Diabetologia 1993; 36: 1293-1298.
27. Serrano-Rios M, Regueiro JR, Serverino R, Lopez-Larrea C, Arnaiz-Villena A. HLA antigens in insulin dependent and non-insulin dependent Spanish diabetic patients. Diabetes Metab 1983; 9: 116-120.
28. Hawrami K, Mohan R, Mohan V, Hitman GA. A genetic study of retinopathy in south Indian Type 2 diabetic patients. Diabetologia 1991; 34: 441-444.
29. Gutierrez C, Vendrell J, Pastor R, Broch M, Aguilar C, Llor C et al. GLUT1 gene polymorphism in non-insulin-dependent diabetes mellitus: genetic susceptibility relationship with cardiovascular risk factors and microangiopathic complications in a Mediterranean population. Diabetes Res Clin Pract 1998; 41: 113-120.
30. Hodgkinson AD, Millward BA, Demaine AG. Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy. kidney Int 2001; 59: 985-989.
31. Liu ZH, Guan TJ, Chen ZH, Li LS. Glucose transporter (GLUT1) allele (XbaI-)associated with nephropathy in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1843-1848.
32. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indian with Type 2 diabetes. Diabetes Care 1997; 20: 1304-1309.
33. Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F, Hansen BV et al. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 2000; 15: 625-630.
34. Hawrami K, Hitman GA, Rema M, Snehalatha C, Viswanathan M, Ramachandran A et al. An association in non-insulin dependent diabetes mellitus subjects between susceptibility to retinopathy and tumour necrosis factor polymorphism. Hum Immunol 1996; 46: 49-54.
35. Sakane N, Yoshida T, Yoshioka K, Kondo M, Sakai Y, Takahashi T. Beta(3)-adrenoreceptor gene polymorphism: a newly defined risk factor for proliferative retinopathy in NIDDM patients. Diabetes 1997; 46: 1633-1636.
36. Vendrell J, Gutierrez C, Broch M, Fernandezal JM, Aguilar C, Richart C. Beta 3-adrenoreceptor gene polymorphism and leptin. Lack of relationship in type 2 diabetic patients. Clin Endocrinol 1998; 49: 679-683.
37. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 1998; 83: 2589-2592.
38. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000; 98: 335-363.
39. Matsubara Y, Murata M, Maruyama T, Handa M, Yamagata N, Watanabe G et al. Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen. Blood 2000; 95: 1560-1564.
40. Alcolado JC, Baroni MG, Li SR, Galton DJ. Genetic variation around the collagen-IV 1A gene locus and proliferative retinopathy in Type 2 diabetes-mellitus. Hum Hered 1993; 43: 126-130.
41. Chen JW, Hansen PM, Tarnow L, Hellgren A, Deckert T, Pociot F. Genetic variation of a collagen IV alpha 1-chain gene polymorphism in Danish insulin-dependent diabetes mellitus (IDDM) patients: lack of association to nephropathy and proliferative retinopathy. Diabetic Med 1997; 14: 143-147.
42. Shcherbak NS, Schwartz EI. The C825T polymorphism in the G-protein beta3 subunit gene diabetic complications in IDDM patients. J Hum Genet 2001; 46: 188-191.
43. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Koulu M, Pesonen U, Mercuri M et al. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000; 108: 235-236.
44. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy Cardiovasc Res 1997; 34: 55-68.
45. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350: 9-13.
46. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry W et al. Impaired endothelial-dependent and independent vasodilation in patients with Tpe 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
47. Cogan DG, Toussaint D, Kuwabarra T et al. Retinal vascular patterns IV. Diabetic retinopathy Arch Ophthalmol 1961; 66: 366-378.
48. Gutierrez C, Vendrell J, Pastor R, Llor C, Aguilar C, Broch M et al. Angiotensin I converting enzyme an angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus. Lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population. Metab Clin Exp 1997; 46: 976-980.
49. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53.
50. Nagi DK, Mansfield MW, Stickland MH, Grant PJ. Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism and diabetic retinopathy in subjects with IDDM and NIDDM. Diabetic Med 1995; 12: 997-1001.
51. Fujisawa T, Ikegami H, Shen GQ, Yamato E, Takekawa K, Nakagawa Y et al. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infraction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995; 18: 983-985.
52. Hanyu O, Hanawa H, Nakagawa O, Tani N, Andou N, Aizawa Y et al. Polymorphism of the angiotensin I-converting enzyme gene in diabetic nephropathy in Type II diabetic patients with proliferative retinopathy. Renal Failure 1998; 20: 125-133.
53. Rabensteiner D, Abrahamian H, Irsigler K, Kiener HP, Mayer G, Kaider A et al. ACE gene polymorphism and proliferative retinopathy in type 1 diabetes: results of a case-control study. Diabetes Care 1999; 22: 1530-1535.
54. Matsumoto A, Iwashima Y, Abiko A, Morikawa A, Sekiguchi M, Eto M et al. Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 2000; 50: 195-202.
55. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995; 44: 489-494.
56. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S et al. Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. Nephrol Dial Transplant 1996; 11: 1019-1023.
57. Sheng H, Ignarro LJ. Biochemical and immunohistochemical characterisation of nitric-oxide synthase in the rat retina. Pharm Res 1996; 33: 29-34.
58. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharm 1999; 126: 391-398.
59. Shao R, Yan W, Rockey DC. Regulation of endothelin-1 synthesis by endothelin converting enzyme-1 during wound healing. J Biol Chem 1999; 274: 3228-3234.
60. Telemaque S, Emoto N, deWit D, Yanagisawa M. In vivo role of endothelin converting enzyme-1 as examined by adeno-virus mediated overexpression in rats. J Cardiovasc Pharmacol 1998; 31: S548-S550.
61. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61: 391-415.
62. Warpeha KM, Xu W, Liu L, Charles IG, Patterson CC, Aht F et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999; 13: 1825-1832.
63. Warpeha KM, Ah-Fat F, Harding S, Patterson CC, Xu W, Hart PM et al. Dinucleotide repeat polymorphisms in EDN1 and NOS3 are not associated with severe diabetic retinopathy in Type 1 and Type 2 diabetes. EYE 1999; 13: 174-178.
64. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor protanoids in rabbit aorta. J Clin Invest 1990; 85: 929-932.
65. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47: 945-952.
66. Graier WF, Wascher TC, Lockner L, Toplak H, Krejs GJ, Kukovetz WR. Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory responses. Diabetes 1993; 42: 1497-1505.
67. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999; 42: 1383-1394.
68. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R et al. Elevated blood pressure and craniofacial abnomalities in mice deficient in endothelin-1. Nature 1994; 368: 703-710.
69. Yanagisawa Y, Yanagisawa M, Kapur R, Richardson JA, Williams SC, Clouthier DE et al. Dual genetic pathways of endothelin-mediated intercellular signalling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 1998; 125: 825-836.
70. Brand M, Le Moullec J-M, Corvol P, Gasc JM. Ontogeny of endothelins-1 and -3. Their receptors, and endothelin converting enzymes-1 in the early human embryo. J Clin Invest 1998; 101: 549-559.
71. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
72. A receptor genes in essential hypertension. J Cardiovasc Pharm 1995; 26: S9-S12.
73. Chakravarthy U, Hayes RG, Stitt AW, Douglas A. Increased ET1 expression in ocular tissues of diabetic animals. Invest Ophthalmol 1997; 38: 2144-2151.